· Published by Health Canada · Official notice
This is duplicated text of a letter from Merck Frosst Canada Ltd.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
October 1, 2004
Subject: Merck Sharp & Dohme (MSD) Announces Voluntary Worldwide Withdrawal of VIOXX® (rofecoxib)
Dear Pharmacist,
MSD announced on September 30, 2004 a voluntary worldwide withdrawal of PrVIOXX® (rofecoxib), its arthritis and acute pain medication. The Company's decision, which is effective immediately, is based on new, three year data from a prospective, randomized, placebo-controlled clinical trial, the APPROVe [Adenomatous Polyp Prevention on VIOXX®] trial.
APPROVe was a multi-center, randomized, placebo-controlled, double-blind study to determine the effect of 156 weeks (3 years) of treatment with VIOXX® on the recurrence of neoplastic polyps of the large bowel in patients with a history of colorectal adenoma. The trial enrolled 2600 patients, and compared VIOXX® 25 mg to placebo. The trial began enrollment in 2000.
The trial, which is being stopped, was designed to evaluate the efficacy of VIOXX® 25 mg in preventing recurrence of colorectal polyps in patients with a history of colorectal adenomas. In this study, there was an increased relative risk for confirmed cardiovascular (CV) events, such as heart attack and stroke, beginning after 18 months of treatment in the patients taking VIOXX® compared to those taking placebo. The results for the first 18 months of the APPROVe study did not show any increased risk of confirmed CV events on VIOXX®, and in this respect are similar to the results of two placebo-controlled studies described in the current labeling for VIOXX®.
"We are taking this action because we believe it best serves the interests of patients," said Raymond Gilmartin, Chairman, President and Chief Executive Office of Merck & Co., Inc., Whitehouse Station, NJ, USA. "Although we believe it may have been possible to continue to market VIOXX® with labeling that would incorporate these new data, given the availability of alternative therapies, and the questions raised by these data, we concluded that a voluntary withdrawal is the responsible course to take."
VIOXX® was launched in Canada in 1999, and has been marketed in over 80 countries. In some countries, the product is marketed under the trademark CEOXX. Worldwide sales of VIOXX® in 2003 were $2.5 billion.
Results of the VIGOR (VIOXX® GI Outcomes Research) study, released in March 2000, demonstrated that the risk of gastrointestinal (GI) toxicity with VIOXX® was less than with naproxen, but indicated an increased risk of cardiovascular events versus naproxen. However, in other studies including our Phase III studies that were the basis of regulatory approval of the product, there was not an increased risk of CV events on VIOXX® compared with placebo or VIOXX® compared with other non-naproxen NSAIDs. Given MSD's commitment to providing additional data that advance scientific knowledge about all of our medicines, MSD began longterm randomized clinical trials to provide an even more comprehensive picture of the cardiovascular safety profile of VIOXX®.
"MSD has always believed that prospective, randomized, controlled clinical trials are the best way to evaluate the safety of medicines. APPROVe is precisely this type of study--and it has provided us with new data on the cardiovascular profile of VIOXX®," said Dr. Peter S. Kim, President, Merck Research Laboratories. "While the cause of these results is uncertain at this time, they suggest an increased risk of confirmed CV events beginning after eighteen months of continuous therapy. While we recognize that VIOXX® benefited many patients, we believe this action is appropriate."
MSD has informed the FDA and regulatory authorities in other countries of its decision. Merck Frosst has informed Health Canada of the worldwide withdrawal. The Company is also in the process of notifying health-care practitioners in countries where VIOXX® is marketed. Patients who are currently taking VIOXX® should contact their health-care providers to discuss discontinuing use of VIOXX® and possible alternative treatments. Please inform your customers of the VIOXX® withdrawal. All dispensing activities (new prescription or renewal) for this product must cease immediately.
Attached is a list of all VIOXX® formulations that were available in Canada (Attachment 1). All products in your possession must be returned collect via Purolator Courier (account no. 5636061) to the following address:
Merck Frosst Canada Ltd.
16711 Transcanada Hwy
Kirkland, P.Q. H9H 3L1
Receiving 1A (att. Returned Goods)
Upon receipt of the merchandise, Merck Frosst Canada Ltd. will issue a credit note for all returned products.
In addition, consumers should be instructed to return their unused tablets or oral solution to their pharmacy. Consumers should not flush unused drugs down the toilet or sink to avoid contaminating ground or municipal water systems.
Patients and health-care professionals may obtain information from http://www.merckfrosst.com or they may call the Merck Frosst Customer Information Centre at 1-800-567-2594.
The results of clinical studies with one molecule in a given class are not necessarily applicable to others in the class. Therefore, the clinical significance of the APPROVe trial, if any, for the long term use of other drugs in this class, consisting of Cox-2 selective inhibitors and NSAIDs, is unknown.
The Canadian Adverse Drug Reaction Monitoring Program at Health Canada is responsible for the collection and assessment of adverse reactions that have been submitted by health-care professionals or consumers either directly or through market authorization holders. In Canada, Health Canada has had a system to gather information on adverse reaction reports since 1965. Information on all reported adverse reactions is maintained in a computerized database. This database is a major tool in the ongoing assessment of marketed therapeutic health products.
Please note that adverse reactions for therapeutic health products marketed in Canada (and foreign reports on the products), including spontaneous reports and Phase IV studies, should be submitted to the Canadian Adverse Drug Reaction Monitoring Program (CADRMP), Marketed Health Products Directorate (MHPD) of the Health Products and Food Branch (HPFB):
Merck Frosst Canada Ltd.
P.O. Box 1005
Pointe Claire - Dorval
Québec H9R 4P8
Telephone: (514) 428-7920
http://www.merckfrosst.com
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
For other inquiries: please refer to contact information.
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
Sincerely,
original signed by
François Bertrand, MD, CM, CSPQ
Executive Director
Medical Research
| Catalogue # | Strength | Format | DIN # |
|---|---|---|---|
| 4420 | 12.5 mg tablet | 30 | 02241107 |
| 4481 | 12.5 mg tablet | 100 | 02241107 |
| 4509 | 12.5 mg tablet | 1000 | 02241107 |
| 4422 | 12.5 mg tablet | 30 | 02241108 |
| 4482 | 12.5 mg tablet | 100 | 02241108 |
| 4510 | 12.5 mg tablet | 1000 | 02241108 |
| 4426 | 12.5 mg/5 mL Oral suspension | 150 mL | 02241109 |